The CMS said it would pay for off-label use of certain cancer drugs for Medicare patients in clinical studies and expand standard Medicare cancer coverage to include use of positron emission tomography in diagnosing cervical cancer. PET also would be covered in clinical trials for use with other forms of cancer. The agency is seeking public comment on both draft coverage decisions. The CMS also announced a one-year, $300 million demonstration project to measure and address three areas of concern for cancer patients -- pain, nausea and vomiting, and fatigue. Providers will receive $130 per patient per day for participating in the project. Read more on about the CMS' cancer-care quality project and its draft decisions on off-label use of certain cancer drugs and PET for various cancers. -- by Tony Fong
CMS to expand cancer coverage, test improvements
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.